SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to its strategic sale of Bressner Technology, which has boosted its cash reserves and sharpened its focus on core AI and edge computing. The community is actively discussing the company's recent stronger-than-expected earnings and raised guidance, alongside high anticipation for a significant military contract for 360 situational awareness systems. Many investors view OSS as an undervalued pure-play in the growing Edge AI and defense sectors, highlighting its tight float and institutional interest.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is drawing significant attention following robust Q3 earnings and strategic moves to bolster its ETF business through acquisitions, alongside its prominent role in a rebounding M&A market. The community is actively discussing the stock's impressive run and strategic AI integration efforts, with many anticipating continued strength, while others debate its high valuation and the potential for a stock split.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bear 3X Shares

LABD is trending amid intense frustration as the biotech sector's (XBI) extended bullish rally continues to defy expectations, leading to significant pressure on this 3x leveraged bear ETF. The community is sharply divided, with many anticipating an imminent, overdue reversal due to XBI's stretched technicals and high RSI, while others caution against fighting the sector's persistent upward momentum.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending sharply higher following the FDA's acceptance of its sNDA for AXS-05 in Alzheimer's disease agitation with Priority Review, setting a PDUFA target in April 2026. This significant regulatory clarity, coupled with positive updates for AXS-12 in narcolepsy and continued strong Auvelity script growth, is fueling widespread optimism among investors. The community is celebrating substantial long-term gains and actively discussing AXSM's potential to become a major CNS powerhouse, anticipating further analyst upgrades and robust performance as the company advances its diverse pipeline and commercial footprint.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences (GLSI) is trending as its directors and officers extended their share lock-up until September 2026, signaling strong insider confidence and aligning with promising preliminary Phase 3 trial data showing a significant reduction in breast cancer recurrence. The community is actively discussing a potential short squeeze, fueled by an extremely high cost-to-borrow and limited shares available, while long-term investors anticipate a strategic transaction or significant valuation re-rating for this low-float biotech.

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals is trending due to the accumulating global regulatory approvals for EKTERLY, its innovative oral on-demand hereditary angioedema treatment, with Japan being the latest market. The community is actively discussing the drug's strong initial sales performance and its significant market advantage as the first oral option, fueling optimism for its global commercialization. Analysts are reinforcing bullish sentiment, recognizing the company's trajectory towards profitability and its strategic position within the biotech sector, with many anticipating further upside.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is currently trending following key regulatory approvals for its Renergen acquisition and new "Overweight" analyst coverage with a bullish price target. Despite these positive developments, community discussion reflects significant frustration over perceived management missteps, repeated commercial shipment delays, and ongoing dilution concerns. This creates a polarized sentiment, balancing long-term potential in critical isotope markets against short-term execution challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Jackson highlighted the rising origination, new capital flow, and the tailwinds that are helping the firm propel forward.</li><li>He stated that the company is well-positioned to address any uncertainties arising from the current environment.</li><li>The CEO noted that, given the company's efficiency and profitability, raising the guidance was a natural outcome.</li></ul>Abacus Global Management Inc. (ABL) recently reported an upbeat third quarter, with the results surpassing Wall Street expectations for the tenth consecutive quarter.Abacus Global reported earnings per share (EPS) of $0.24 in the third quarter (Q3), compared to an estimated EPS of $0.18, according to Stocktwits data. Its revenue stood at $63 million during the quarter, compared to a Street estimate of $50.2 million.<a href="https://stocktwits.com/symbol/ABL">Abacus Global shares</a> were up more than 4% in Monday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘extremely bullish’ territory at the time of writing.Stocktwits caught up with CEO Jay Jackson to understand what drove Abacus Global’s Q3 performance, and what lies ahead for the company.We would like to start with your thoughts on Q3 performance, as well as the longevity of the product in the Middle East.We had an incredibly productive Q3. That was our 10th consecutive quarter in a row where we had exceeded earnings expectations related to consensus. So, we're incredibly proud of that. What's interesting about that statistic is that, actually, six of those quarters we beat earnings estimates by over 30%, including Q3, primarily driven by our continued efforts to expand our message and reach new investors and policyholders.We're seeing our origination tick up. We're also seeing new capital coming into the asset. But most importantly, from a market perspective, I think we've also got some wind at our backs. Specifically, around the premise that people are seeking uncorrelated assets. There's almost a flight to safety and other kinds of assets. And this is an uncorrelated yielding product. And now we're starting to see investors really lean into this asset class. I think that's also helping drive our success right now. And we foresee this continuing.The company's business is evolving slightly from a niche life settlement player to the broader alternative asset management and wealth management segments. What’s driving this transformation?I think that was always kind of the natural evolution of our company, which is that we provide a very distinct service initially to policyholders, and that service is helping them monetize or understand the liquidity in their life insurance policy through its current market value.If the number one fear in retirement is running out of money, wouldn't you like to know how long you're going to be in retirement? Right? So, our underwriting is being applied in multiple ways. But in addition to that, institutional asset management firms, banks, etc., have been looking for this kind of yield.How do you plan to sustain this momentum?One, there's a huge amount of excitement around investing in uncorrelated assets. Just look at the price of gold. Gold's what, $4,000 now, right? You could look at alternative assets, whether it's private credit, [they’ve] raised billions. So I think that there's a lot of room to go here, and quite frankly, we're just scratching the surface. Our expectation is that there will be billions and billions of dollars in assets under management with our firm.We expect people to continue seeking this kind of asset, and don't forget that we're the originator. We're the market maker of that asset. So, they have to come to us, and now they're investing directly.Amid this evolution, the company announced a dividend and share buyback. How do you strike a balance between distributing capital and reinvesting in the company's future growth?We felt it was the right time, and the reason was that as we've seen our business evolve, we wanted to reward our shareholders appropriately. If you look at the formula that we put out in our press release, we actually put out a pretty conservative dividend. It's only a little over 20% of our adjusted net income.We have excess capital to deploy, and we took that excess capital and capitalized our shareholders through our recurring revenues. We think that's the right way to conduct ourselves as an alternative asset manager and should be rewarding our shareholders on an annual basis.Regarding the disconnect in valuation, what do you think retail investors and institutions are missing out on?It’s really an education issue, and it's not just institutions; it's retail, it's across the board in understanding that first and foremost, life insurance is an asset. People treat it as something that they never want to use or as a piece of debt. They don't see it, oh, this is just like any other form of private credit. And so that's why that disconnect exists.That education has to start at the core level, and that takes time. We've spent the last three years doing that, and that message is really starting to resonate.We're right at the precipice of what I think is a breakout. And it's coming from institutions, which are really starting to get this business, retail investors who are kind of nodding their heads and saying, "Oh, I really do get this now."What was the driving factor behind raising FY25 net income guidance?I would say the driving factor for us continuing to increase our guidance is predominantly driven by market forces, in a sense. We are [also] becoming more efficient in our underlying business.We run an incredibly efficient and profitable business. And so I think when you look at the raise on our guidance, that was a natural outcome.The average realized gain in Q3 was around 37%, up from 26% in Q2. Is this due to efficiency, or is there another factor driving it? Do you think this is sustainable?I think it's definitely driven by efficiency, but you'll see it vary quarter to quarter. I mean, if you go back a few more quarters, you'll see that number hover between the 20% to 25% range. And I think that this was an exceptional quarter in Q3, partly driven by our efficiencies, partly driven by market factors.There's a lot of uncertainty regarding rates, and people are still not sure if there will be a hard landing or a recession. How are you going to tackle this sort of uncertainty going forward?We're in a great spot for that kind of uncertainty. I mean, consider the asset. We would benefit in two ways. Actually, both sides of our transaction.One, if you're a policyholder and we're in a recession, and you're seeking liquidity, which means you'll look to places that you may not have considered in the past, such as your life insurance policy, to seek liquidity where you haven't done so before. Originations will more than likely tick up during a recession.The second piece that investors seek during a recessionary environment, like a volatile market or a pullback, is uncorrelated assets.What makes you distinct from your competitors, and can you explain the competitive advantage you have?We're the only public company in our entire industry, and that gives us a significant advantage from both a cost of capital and an efficiency perspective. You know we're always driving our growth, because as a public company, you know you're reporting every quarter, and so being innovative is super important.The interview has been edited for clarity and length.<a href="https://stocktwits.com/symbol/ABL">ABL stock</a> is down 18% year-to-date and 27% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dow-futures-rise-senate-votes-to-end-government-shutdown/cLPcKrVRE22">Dow Futures Rise As Senate Votes To End Government Shutdown: MTSR, VSAT, RUM, TSM Among Stocks To Watch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retirement planning representational image

Exclusive: Abacus Global CEO Jay Jackson Eyes Billions In AUM, Explains How The Company Plans To Bridge The Valuation Disconnect

In an exclusive conversation with Stocktwits, Jackson lays out what drove Abacus Global’s performance, the market opportunity ahead, and what makes the company distinct from its competitors.

Current Price	$19.60
Prev Close	$19.64
Open	$19.60
Dividend Yield	N/A
50-Day Moving Average	$19.76
Beta	N/A
Avg. Volume	1,534.58
PE Ratio	N/A

52-Week High	$20.00
52-Week Low	$17.11
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

ABXB
Abacus Flexible Bond Leaders ETF

Feed

News

Sentiment

Fundamentals

Info

Latest ABXB News

ABXBAbacus Flexible Bond Leaders ETF